BiotechTube

SHR-1210

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nasopharyngeal Carcinoma

Conditions

Nasopharyngeal Carcinoma

Trial Timeline

Aug 14, 2018 → Dec 30, 2021

NCT ID
NCT03558191

About SHR-1210

SHR-1210 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Nasopharyngeal Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03558191. Target conditions include Nasopharyngeal Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (9)

NCT IDPhaseStatus
NCT03558191Phase 2Completed
NCT03557411Phase 2UNKNOWN
NCT03363555Phase 2UNKNOWN
NCT03222440Pre-clinicalCompleted
NCT03155425Phase 2Completed
NCT03085069Phase 2UNKNOWN
NCT02989922Phase 2Completed
NCT02738489Phase 1Completed
NCT02721589Phase 1Completed

Competing Products

20 competing products in Nasopharyngeal Carcinoma

See all competitors
ProductCompanyStageHype Score
Nanatinostat + Valganciclovir + PembrolizumabViracta TherapeuticsPhase 1
25
Cisplatin 2 + Docetaxel + Cisplatin 1Sun PharmaceuticalPhase 2
52
CisplatinSun PharmaceuticalPhase 3
77
Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
77
5-fu + Lobaplatin + Placebo + leucogenSun PharmaceuticalPhase 3
77
CapecitabineSun PharmaceuticalPhase 3
77
Amifostine every-other-day regimen + Amifostine everyday regimenSun PharmaceuticalPhase 2
52
Nedaplatin + CisplatinSun PharmaceuticalPhase 3
77
PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
77
QL1706 + Gemcitabine + CisplatinSun PharmaceuticalPhase 3
77
The combination treatment of anlotinib, penpulimab and capecitabine.Sun PharmaceuticalPhase 2
52
docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracilSun PharmaceuticalPhase 3
77
Pemetrexed (Alimta)Eli LillyPhase 2
52
Camrelizumab + Placebos + Gemcitabine + CisplatinJiangsu Hengrui MedicinePhase 3
77
Famitinib + CisplatinJiangsu Hengrui MedicinePhase 1
33
SHR-1210 + Gemcitabine + cis-platinumJiangsu Hengrui MedicinePhase 1
33
SHR-1701 + Gemcitabine + Cisplatin + Albumin PaclitaxelJiangsu Hengrui MedicinePhase 1
33
FamitinibJiangsu Hengrui MedicinePhase 2
52
ApatinibJiangsu Hengrui MedicinePhase 2
52
SHR-1701 + FamitinibJiangsu Hengrui MedicinePhase 1/2
41

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85